KEMCO

Disruption in the Middle East Weighed on MakeMyTrip (MMYT)

Artisan Partners, an investment management company, released its third-quarter 2026 investor letter for the “Artisan Developing World Fund”. The letter can be downloaded here. The Artisan Developing World Fund (Investor Class) returned 3.50% in the quarter ending September 30, 2026, outperforming the MSCI Emerging Markets Index’s -0.37%. Since June 30, 2015, its cumulative returns have […]

FDA Expands Approval for Eli Lilly Therapy in Untreated Leukemia Patients

FDA approves Eli Lilly's Jaypirca for adults with untreated CLL/SLL without 17p deletion based on Phase 3 BRUIN CLL-313 trial results.

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. This approval allows for the use of Jaypirca as a first-line treatment for appropriate patients

Eli Lilly Says FDA Approves Additional Indication For Jaypirca, Non-Covalent BTK Inhibitor, For Treatment Of Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton

Hochul leads Blakeman in polls, gets boost from Mamdani

McDonald's CEO Chris Kempczinski says more adults are buying Happy Meals as GLP-1 drugs shrink appetites

GLP-1 drugs work by making users feel full on less food. Even so, many users are still visiting their favorite chain and ordering less.

Kura spins diabetes work into a Lilly-backed biotech startup

Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.

Alphabet Stock Rises as Google Avoids Another Business Breakup Attempt

Shares of Alphabet rose Wednesday after a federal judge rejected a Justice Department request that Google sell its online advertising business. Alphabet stock advanced 1% to $338.51 on Wednesday, while the and the both gained 0.5%. Judge Leonie Brinkema on Wednesday dismissed the Trump administration’s move to force Google to sell AdX, the company’s online exchange tool for publishers and advertisers.

Judge orders changes to Google's digital ads business but spares it from a breakup

A federal judge on Wednesday ordered Google to retool the system powering its monopoly in digital advertising, sparing the company from a wrenching breakup sought by the U.S. government. The initial two-page decision by U.S. District Judge Leonie Brinkema in Virginia marks the second time in a year that Google has received a reprieve from a Justice Department proposal to dismantle its internet empire. Meanwhile, what courts have described as the company's anti-competitive practices have enriched Google's corporate parent, Alphabet Inc., which has a market value of $4.11 trillion.

Smartkem shares are trading lower. The company announced a non-binding letter of intent to acquire all outstanding shares of Carbonium Core in exchange for shares of Smartkem Series B Convertible Preferred Stock.